{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044829","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.881047+00:00","generated_at":"2026-05-30T02:26:59.967832+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sanara MedTech Q3 revenue up 35% to $21.7M, net loss widens to $2.9M","bullets":["Net revenue rose 35% YoY to $21.7M; net loss of $2.9M vs $1.1M loss in Q3 2023.","Adjusted EBITDA improved to $0.8M from $0.3M in prior-year quarter.","Appointed Keith Myers (former LHC Group CEO) to the board; invested $5.0M in ChemoMouthpiece for 6.64% stake and exclusive U.S. distribution.","Products now sold in over 1,200 facilities; contracted in 4,000+ hospitals; distributor network expanded to 300+."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044829","json":"https://secwatch.observer/filing/0001493152-24-044829.json","markdown":"https://secwatch.observer/filing/0001493152-24-044829.md","text":"https://secwatch.observer/filing/0001493152-24-044829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315224044829/0001493152-24-044829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315224044829/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:26:59.967832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}